Dianthus Therapeutics, Inc. /DE/ Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

Dianthus Therapeutics, Inc. /DE/ reported Revenue From Contract With Customer Excluding Assessed Tax of $2.04 million for the year ending 2025.

  • Dianthus Therapeutics, Inc. /DE/ showed a decrease of -67.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2023 to 2025), Dianthus Therapeutics, Inc. /DE/'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 28.0%.
  • Historical annual values: Fiscal year 2025: $2.04 million | Fiscal year 2024: $6.24 million | Fiscal year 2023: $2.83 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: